San Diego-dependent Viking Therapeutics marked alone as a serious competitor inside the weight loss drug current market in February soon after revealing promising information from a mid-phase trial of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when given for a weekly injection and in March the co